Lampert EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study. Clin Cancer Res 2020 May 12. pii: 1078-0432.CCR-20-0056.
PMID: 32398324